Novo Nordisk Wegovy Pill Launches in U.S.
Novo Nordisk Wegovy pill debuts in the U.S. with pharmacy and telehealth distribution and a $149 self-pay tier that shapes near-term revenue.
KEY TAKEAWAYS
- Wegovy pill launched in the U.S., available through pharmacies and telehealth partners.
- Self-pay price $149 per month; retail band $149-$299.
- OASIS 4 reported about 17.0% average weight loss among patients who remained on treatment.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novo Nordisk launched the Wegovy pill in the U.S. on Jan. 5, 2026 (ET), making the oral GLP-1 weight-loss medicine broadly available through pharmacies and telehealth partners. This rollout expands commercial access as the U.K. regulator reviews the drug.
U.S. Launch and Commercial Distribution
Novo Nordisk made the oral semaglutide tablet widely accessible across the U.S., distributing it through more than 70,000 pharmacies, including CVS and Costco, as well as NovoCare Pharmacy and GoodRx. The pill is also available via telehealth platforms Ro, LifeMD, and Weight Watchers. LifeMD expanded its partnership to include the Wegovy pill in its virtual weight-management services. This network integrates retail and digital channels, offering adults seeking obesity treatment immediate access outside traditional clinics.
The company set a self-pay price of $149 per month for the 1.5 mg and 4 mg doses, with retail pricing ranging up to $299 per month. By establishing a clear launch price and retail band, Novo Nordisk provides pharmacies and telehealth partners a commercial reference as they route prescriptions and enroll patients.
Clinical Data and Regulatory Outlook
The U.S. Food and Drug Administration approved the 25 mg oral semaglutide tablet on Dec. 22, 2025 (ET), authorizing Wegovy as the first oral GLP-1 weight-loss pill for chronic weight management in adults with obesity or overweight plus weight-related conditions. The label specifies use alongside a reduced-calorie diet and increased physical activity. This oral formulation extends Novo Nordisk’s GLP-1 franchise into a pill intended for routine outpatient prescribing.
Data from the OASIS 4 trial showed average weight loss of about 17.0% among participants who remained on treatment. An alternate analysis reported roughly 14.0% average weight loss regardless of retention. These efficacy figures are likely to influence discussions among telehealth providers, pharmacies, and patients as the product gains wider adoption.
The U.K. Medicines and Healthcare products Regulatory Agency is reviewing an application for the 25 mg oral Wegovy and expects a decision by Dec. 31, 2026. Approval by that date would mark a key regulatory milestone, enabling broader international availability beyond the U.S. market.
